EMEA-000118-PIP04-17

Key facts

Invented name
Orencia
Active substance
Abatacept
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0183/2018
PIP number
EMEA-000118-PIP04-17
Pharmaceutical form(s)
  • Powder for concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Bristol-Myers Squibb / Pfizer EEIG

E-mail: medical.information@bms.com
Tel. +44 (0)1895 523740

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating